- Oct 19 Wed 2011 07:16
- Sep 27 Tue 2011 05:59
The European Medicines Agency (EMA) recommends restricting the use of the antiarrhythmic medication dronedarone (Multaq, Sanofi-Aventis) . The committee states that because of the increased risk of liver, lung, and cardiovascular adverse events, dronedarone "should only be prescribed after alternative treatment options have been considered." Patients currently taking dronedarone should have their treatment reassessed by their physician at their next scheduled visit, the EMA reports.
- Sep 26 Mon 2011 05:56
The US Food and Drug Administration (FDA) today approved eculizumab (Soliris, Alexion Pharmaceuticals) as the first drug to treat atypical hemolytic uremic syndrome (aHUS), a rare and chronic blood disease that disproportionately affects children.
- Sep 25 Sun 2011 05:53
The European Medicines Agency has changed its recommendations for suppositories that contain terpenic derivatives. It now says that they should not be used in children younger than 30 months or in children who have experienced febrile convulsion, epilepsy, or recent anorectal lesions.
- Sep 23 Fri 2011 05:20
Arch Dermatol. 2011; 147(8):917-21 (ISSN: 1538-3652)
Fanelli M; Kupperman E; Lautenbach E; Edelstein PH; Margolis DJ
Department of Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 815 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104. firstname.lastname@example.org.
- Sep 22 Thu 2011 05:58
On August 10, the US Food and Drug Administration (FDA) approved Complera, a combination of the nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir and emtricitabine, for treatment of HIV infection. This combination drug results in the same blood levels as each of the 3 drugs individually, according to the findings of a bioequivalence study. Approval of Complera was based on the ECHO and THRIVE phase 3 randomized trials of rilpivirine, without performance of any new trials.
- Sep 11 Sun 2011 05:01
INTRODUCTION: HIV infection is a disease associated with chronic inflammation and immune activation. Antiretroviral therapy reduces inflammation, but not to levels in comparable HIV-negative individuals. The HMG-coenzyme A reductase inhibitors (statins) inhibit several pro-inflammatory processes and suppress immune activation, and are a logical therapy to assess for a possible salutary effect on HIV disease progression and outcomes.
- Sep 10 Sat 2011 10:06
A new set of evidence-based guidelinesprovides an algorithm for reducing colchicine doses to prevent toxicity in patients who are also taking drugs such as cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil extended release (ER), or diltiazem ER. The research group was led by Robert A. Terkeltaub, MD, from the Veterans Administration San Diego Medical Center in California, and the new report appears in the August issue of Arthritis & Rheumatism.
- Sep 09 Fri 2011 10:08
Abstract and Introduction
The literature suggesting a relevant interaction between acetaminophen and warfarin is inconsistent. Considering the ubiquitous use of acetaminophen, a review of the effects on international normalized ratio (INR) in patients taking warfarin was necessary. Thus, we performed a search of the PubMed (1966–November 2010) and International Pharmaceutical Abstracts (1970–November 2010) databases to review the available literature addressing an acetaminophen-warfarin interaction and its possible mechanisms.
- Sep 08 Thu 2011 07:38
The boxed warning on the labels of all tumor necrosis factor alpha (TNF-alpha) inhibitors will be updated to warn about the risk for serious and sometimes fatal infection from 2 bacterial pathogens,Legionella and Listeria, the US Food and Drug Administration (FDA) announced today.
- Sep 02 Fri 2011 05:12
An investigational radiopharmaceutical has been found to improve survival in patients with advanced prostate cancer in a phase 3 study that is still ongoing. Only 4 other products have managed to show such a survival benefit.
- Aug 08 Mon 2011 07:03
Physicians generally should avoid prescribing either methylene blue or linezolid (Zyvox,Pfizer) in combination with serotonergic agents such as paroxetine or duloxetine to avoid a potential drug interaction causing a dangerous condition called serotonin syndrome, the US Food and Drug Administration (FDA) announced today.
- Aug 07 Sun 2011 08:17
Please clarify the use of probiotics with concomitant antibiotic therapy. I see this combination in practice and am unclear whether it has clinical benefit for preventing antibiotic-associated diarrhea.
- Jul 25 Mon 2011 08:28
- Jul 22 Fri 2011 09:41
The risk for Guillain-Barré syndrome is not increased after use of adjuvanted pandemic influenza (H1N1) 2009 vaccine, but the upper limit does not exclude a potential increase in risk up to 2.7-fold, according to the results of a multinational case-control study reported online July 12 in the BMJ.